Retatrutide and tirzepatide: what’s different?
Two important names in metabolic health. Different stages of the journey.
The form
Preparation matters
The routine
No personal schedule is set by this guide.
The evidence
See the evidence and source notes below.
Research, approval and availability are separate questions.
On this page
A linked source is not a clinical endorsement. How we handle review and corrections.
A third pathway is part of the interest
Both medicines work through hormone pathways involved in metabolic health. Retatrutide adds activity at the glucagon receptor. More receptors alone do not prove a medicine is better; outcomes, tolerability and the person’s health history all matter.
Availability is the practical difference today
| Question | Retatrutide (Reta) | Tirzepatide (Zepbound) |
|---|---|---|
| FDA status | Investigational | Approved prescription product |
| Receptors | GLP-1, GIP, glucagon | GLP-1, GIP |
| Next step | Follow approval and availability updates | Discuss the approved treatment with a licensed clinician |
Why we don’t rank drugs by separate trials
Trials can differ in who enrolls, how long treatment lasts and how results are analyzed. A percentage from one study is not a direct comparison with a percentage from another. A treatment decision also includes safety, cost and whether someone can continue treatment.
Stay ready for what comes next
Join the Goodmorrow Reta list for future availability updates, or read our tirzepatide guide to explore an approved option with your clinician.
Questions people ask
When will retatrutide be FDA-approved?
There is no announced FDA approval date. Lilly has stated that it plans to submit retatrutide in the U.S. in the first quarter of 2027. Filing, approval and pharmacy availability are separate steps. Information checked October 29, 2026.
Is the interest list free?
Yes. Join for retatrutide research, approval and Goodmorrow availability updates by email. No payment or health history is needed. Joining does not reserve supply or guarantee treatment. Medication pricing and eligibility will depend on any eventual approval, supply and clinical assessment.
Sources
- Manufacturer informationTRIUMPH-1 results for weight, knee osteoarthritis and sleep apnea Eli Lilly (trial sponsor), June 6, 2026
- Manufacturer informationTirzepatide (Zepbound) prescribing information Eli Lilly, Prescribing information checked October 6, 2026
- Manufacturer informationRetatrutide phase 3 results and planned U.S. submission in Q1 2027 Eli Lilly, July 23, 2026
Good days ahead.
Join the opening list for appointment updates.